07:00 , Aug 27, 2007 |  BioCentury  |  Tools & Techniques

Harnessing sodium channels

Sodium channels are large voltage-gated transmembrane proteins that play an important role in many physiological processes by regulating the entry and exit of charged ions. Because of this role as ion gatekeepers, they have proven...
07:00 , Sep 5, 2000 |  BC Week In Review  |  Company News

NPS, Forest Laboratories deal

NPSP's NPS Allelix Corp. subsidiary (Toronto, Ontario) granted FRX exclusive worldwide development and marketing rights to its ALX-0646 selective serotonin agonist to treat migraine. The product has completed Phase I testing outside the U.S. Packard...
07:00 , Aug 7, 2000 |  BC Week In Review  |  Company News

Icagen, NPS Allelix, University of California deal

ICAgen received from NPS Allelix, a subsidiary of NPS Pharmaceuticals Inc. (NPSP; TSE:NX, Salt Lake City, Utah), an exclusive license to sodium channels expressed in peripheral nerve cells that regulate cellular excitability in pain pathways....
08:00 , Feb 7, 2000 |  BC Week In Review  |  Company News

NPS Pharmaceuticals Inc other research news

NPSP's NPS Allelix Corp. subsidiary (Toronto, Ontario) said that osteoblasts cultured in microgravity produced 22 percent less bone compared to cells cultured on Earth, but that ALX 1-11 improved bone growth in microgravity by 68...
07:00 , Oct 4, 1999 |  BC Week In Review  |  Company News

Allelix, NPS deal

The companies will merge, with NPSP issuing 0.3238 shares of stock for each share of AXB stock, for a total of 6.5 million NPSP shares. AXB shareholders will own about one-third of the new company,...
07:00 , Oct 4, 1999 |  BioCentury  |  Strategy

NPS-Allelix plot their escape

Merger partners NPS Pharmaceuticals Inc. and Allelix Biopharmaceuticals Inc. hope to break their dependence on royalty-based partnerships by focusing their combined resources on their unpartnered late-stage products, while escaping the shadows that hide companies with...